Literature DB >> 10780515

Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden.

M Aström1, L Bodin, I Nilsson, U Tidefelt.   

Abstract

With the aim of describing an unselected series of acute myeloid leukaemias (AML) in adults, patients diagnosed 1987-1992 in the Orebro region of central Sweden were reviewed by investigating hospital records. By utilizing: (1) The Swedish Cancer Registry, (2) The Cause of Death Registry, (3) listings of pathology bone marrow reports and (4) listings of inpatient discharge diagnoses, we attempted to find all patients. Among secondary AML, only blast-crises of CML were excluded. A total of 214 cases of AML with a median age of 69.5 years were verified corresponding to a mean yearly incidence in adults of 5.4/100 000. Of all patients, 56% had received 'high-dose' induction treatment, 28% 'low-dose' treatment and 16% no cytostatic treatment. Median survival for all patients was 5.8 months and the probability of survival at 5 years was 9.3%. The 120 'high-dose' treated patients had a total CR rate of 67%, median CR duration 10.1 months and median survival 11.4 months. Age, LDH and kidney function were found to be independent prognostic variables for survival. The inclusion of patients unreferred from district hospitals makes this study unique as an example of unselected AML.

Entities:  

Mesh:

Year:  2000        PMID: 10780515      PMCID: PMC2363361          DOI: 10.1054/bjoc.1999.1123

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

2.  Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission.

Authors:  H Brincker
Journal:  Cancer Treat Rep       Date:  1985-01

3.  A stage classification for prognosis in adult acute myelogenous leukaemia based upon patients' age, bone marrow karyotype and clinical features.

Authors:  P Bernard; J Reiffers; F Lacombe; D Dachary; M R Boisseau; A Broustet
Journal:  Scand J Haematol       Date:  1984-04

4.  Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation.

Authors:  H Bartelink; J C Horiot; P Poortmans; H Struikmans; W Van den Bogaert; I Barillot; A Fourquet; J Borger; J Jager; W Hoogenraad; L Collette; M Pierart
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

5.  The leukaemia research fund data collection survey: the incidence and geographical distribution of acute myeloid leukemia.

Authors:  P A McKinney; F E Alexander; R A Cartwright; T J Ricketts
Journal:  Leukemia       Date:  1989-12       Impact factor: 11.528

6.  Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases.

Authors:  P Fenaux; C Preudhomme; J L Laï; P Morel; R Beuscart; F Bauters
Journal:  Br J Haematol       Date:  1989-09       Impact factor: 6.998

7.  Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival.

Authors:  J P Dutcher; C A Schiffer; P H Wiernik
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

8.  Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation.

Authors:  L Boros; C Chuang; F O Butler; J M Bennett
Journal:  Cancer       Date:  1985-11-01       Impact factor: 6.860

9.  Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia.

Authors:  E Estey; T L Smith; M J Keating; K B McCredie; E A Gehan; E J Freireich
Journal:  Leukemia       Date:  1989-04       Impact factor: 11.528

10.  Acute leukaemia in a defined geographic area--incidence, clinical history and prognosis.

Authors:  A Ost; P Lindström; B Christensson; H Gyllenhammar; L Engsted
Journal:  Scand J Haematol       Date:  1984-08
View more
  5 in total

1.  Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis.

Authors:  Tea Reljic; Marina Sehovic; Jeffrey Lancet; Jongphil Kim; Najla Al Ali; Benjamin Djulbegovic; Martine Extermann
Journal:  J Geriatr Oncol       Date:  2020-07-12       Impact factor: 3.599

2.  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Authors:  Mikkael A Sekeres; Gordon Guyatt; Gregory Abel; Shabbir Alibhai; Jessica K Altman; Rena Buckstein; Hannah Choe; Pinkal Desai; Harry Erba; Christopher S Hourigan; Thomas W LeBlanc; Mark Litzow; Janet MacEachern; Laura C Michaelis; Sudipto Mukherjee; Kristen O'Dwyer; Ashley Rosko; Richard Stone; Arnav Agarwal; L E Colunga-Lozano; Yaping Chang; QiuKui Hao; Romina Brignardello-Petersen
Journal:  Blood Adv       Date:  2020-08-11

3.  Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.

Authors:  J M Sargent; A W Elgie; C J Williamson; G M Lewandowicz; C G Taylor
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

4.  Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.

Authors:  David Martínez-Cuadrón; Juan E Megías-Vericat; Josefina Serrano; Pilar Martínez-Sánchez; Eduardo Rodríguez-Arbolí; Cristina Gil; Eliana Aguiar; Juan Bergua; José L López-Lorenzo; Teresa Bernal; Ana Espadana; Mercedes Colorado; Carlos Rodríguez-Medina; María López-Pavía; Mar Tormo; Lorenzo Algarra; María-Luz Amigo; María J Sayas; Jorge Labrador; Juan I Rodríguez-Gutiérrez; Celina Benavente; Lissette Costilla-Barriga; Raimundo García-Boyero; Esperanza Lavilla-Rubira; Susana Vives; Pilar Herrera; Daniel García-Belmonte; María Mar Herráez; Graça Vasconcelos Esteves; Maria I Gómez-Roncero; Ana Cabello; Guiomar Bautista; Amaia Balerdi; José Mariz; Blanca Boluda; Miguel Á Sanz; Pau Montesinos
Journal:  Blood Adv       Date:  2022-02-22

5.  Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study.

Authors:  Antonio Solana-Altabella; Juan Eduardo Megías-Vericat; Octavio Ballesta-López; Blanca Boluda; Isabel Cano; Evelyn Acuña-Cruz; Rebeca Rodríguez-Veiga; Laura Torres-Miñana; Claudia Sargas; Miguel Á Sanz; Carmela Borrell-García; Eduardo López-Briz; José Luis Poveda-Andrés; Javier De la Rubia; Pau Montesinos; David Martínez-Cuadrón
Journal:  Cancers (Basel)       Date:  2022-04-11       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.